Second Primary Cancers After Liver, Gallbladder and Bile Duct Cancers, and These Cancers as Second Primary Cancers

References

• Hamilton S, Aaltonen L, editors. Tumours of the Digestive System. Lyon: IARC; 2000.
   Google Scholar
• Villanueva A, Longo DL. Hepatocellular carcinoma. N Engl J Med. 2019;380(15):1450–1462. doi:10.1056/NEJMra171326330970190
   PubMed Web of Science ®Google Scholar
• IARC. GLOBOCAN 2000. Cancer Incidence, Mortality and Prevalence Worldwide. Lyon: IARC Press; 2001.
   Google Scholar
• Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16(10):589–604. doi:10.1038/s41575-019-0186-y31439937
   PubMed Web of Science ®Google Scholar
• Takakura K, Oikawa T, Nakano M, et al. Recent insights into the multiple pathways driving non-alcoholic steatohepatitis-derived hepatocellular carcinoma. Front Oncol. 2019;9:762. doi:10.3389/fonc.2019.0076231456946
   PubMed Web of Science ®Google Scholar
• Åberg F, Färkkilä M, Männistö V. Interaction between alcohol use and metabolic risk factors for liver disease: a critical review of epidemiological studies. Alcohol Clin Exp Res. 2020;44(2):384–403. doi:10.1111/acer.1427131854001
   PubMed Web of Science ®Google Scholar
• Thylur RP, Roy SK, Shrivastava A, LaVeist TA, Shankar S, Srivastava RK. Assessment of risk factors, and racial and ethnic differences in hepatocellular carcinoma. JGH Open. 2020;4(3):351–359. doi:10.1002/jgh3.1233632514436
   PubMed Web of Science ®Google Scholar
• Rawla P, Sunkara T, Thandra KC, Barsouk A. Epidemiology of gallbladder cancer. Clin Exp Hepatol. 2019;5(2):93–102. doi:10.5114/ceh.2019.8516631501784
   PubMed Web of Science ®Google Scholar
• Bal MM, Ramadwar M, Deodhar K, Shrikhande S. Pathology of gallbladder carcinoma: current understanding and new perspectives. Pathol Oncol Res. 2015;21(3):509–525. doi:10.1007/s12253-014-9886-325618479
   PubMed Web of Science ®Google Scholar
• Arnold M, Pandeya N, Byrnes G, et al. Global burden of cancer attributable to high body-mass index in 2012: a population-based study. Lancet Oncol. 2015;16(1):36–46. doi:10.1016/S1470-2045(14)71123-425467404
   PubMed Web of Science ®Google Scholar
• Hemminki K, Li X. Familial liver and gall bladder cancer: a nationwide epidemiological study from Sweden. Gut. 2003;52:592–596. doi:10.1136/gut.52.4.59212631675
   PubMed Web of Science ®Google Scholar
• Yu MW, Chang HC, Liaw YF, et al. Familial risk of hepatocellular carcinoma among chronic hepatitis B carriers and their relatives. J Natl Cancer Inst. 2000;92(14):1159–1164. doi:10.1093/jnci/92.14.115910904089
   PubMedGoogle Scholar
• Petersen G. Familial aggregation: sorting susceptibility from shared environment. J Natl Cancer Inst. 2000;92:1114–1115. doi:10.1093/jnci/92.14.111410904078
   PubMedGoogle Scholar
• Castro FA, Liu X, Försti A, et al. Increased risk of hepatobiliary cancers after hospitalization for autoimmune disease. Clin Gastroenterol Hepatol. 2014;12(6):1038–1045.e7. doi:10.1016/j.cgh.2013.11.00724246767
   PubMed Web of Science ®Google Scholar
• McGee EE, Castro FA, Engels EA, et al. Associations between autoimmune conditions and hepatobiliary cancer risk among elderly US adults. Int J Cancer. 2019;144(4):707–717. doi:10.1002/ijc.3183530155920
   PubMed Web of Science ®Google Scholar
• Møller P, Seppälä TT, Bernstein I, et al. Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the prospective lynch syndrome database. Gut. 2018;67(7):1306–1316. doi:10.1136/gutjnl-2017-31405728754778
   PubMed Web of Science ®Google Scholar
• Mousavi SM, Hemminki K. Cancer incidence, trends, and survival among immigrants to Sweden: a population-based study. Eur J Cancer Prev. 2015;24(Suppl 1):S1–S63. doi:10.1097/CEJ.000000000000010625599121
   PubMed Web of Science ®Google Scholar
• Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010;46(4):765–781. doi:10.1016/j.ejca.2009.12.01420116997
   PubMed Web of Science ®Google Scholar
• Travis LB, Demark Wahnefried W, Allan JM, Wood ME, Ng AK. Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors. Nat Rev Clin Oncol. 2013;10(5):289–301. doi:10.1038/nrclinonc.2013.4123529000
   PubMed Web of Science ®Google Scholar
• Chen T, Fallah M, Jansen L, et al. Distribution and risk of the second discordant primary cancers combined after a specific first primary cancer in German and Swedish cancer registries. Cancer Lett. 2015;369(1):152–166. doi:10.1016/j.canlet.2015.08.01426319898
   PubMed Web of Science ®Google Scholar
• Wu WC, Chen YT, Hwang CY, et al. Second primary cancers in patients with hepatocellular carcinoma: a nationwide cohort study in Taiwan. Liver Int. 2013;33(4):616–623. doi:10.1111/liv.1210323331767
   PubMed Web of Science ®Google Scholar
• Zheng G, Sundquist K, Sundquist J, Försti A, Hemminki A, Hemminki K. Rate differences between first and second primary cancers may outline immune dysfunction as a key risk factor. Cancer Med. 2020;9(21):8258–8265.32960498
   PubMed Web of Science ®Google Scholar
• Zheng G, Sundquist K, Sundquist J, Försti A, Hemminki A, Hemminki K. Incidence differences between first primary cancers and second primary cancers following skin squamous cell carcinoma as etiological clues. Clin Epidemiol. 2020;12:857–864. doi:10.2147/CLEP.S25666232821171
   PubMed Web of Science ®Google Scholar
• Greenland S, Senn SJ, Rothman KJ, et al. Statistical tests, P values, confidence intervals, and power: a guide to misinterpretations. Eur J Epidemiol. 2016;31(4):337–350. doi:10.1007/s10654-016-0149-327209009
   PubMed Web of Science ®Google Scholar
• Henriksson M, Björnsson B, Sternby Eilard M, et al. Treatment patterns and survival in patients with hepatocellular carcinoma in the Swedish national registry SweLiv. BJS Open. 2020;4(1):109–117. doi:10.1002/bjs5.5022632011814
   PubMed Web of Science ®Google Scholar
• Ji J, Sundquist K, Sundquist J, Hemminki K. Comparability of cancer identification among death registry, cancer registry and hospital discharge registry. Int J Cancer. 2012;131:2085–2093. doi:10.1002/ijc.2746222307919
   PubMed Web of Science ®Google Scholar
• Thomsen H, Li X, Sundquist K, Sundquist J, Försti A, Hemminki K. Familial associations between autoimmune hepatitis and primary biliary cholangitis and other autoimmune diseases. PLoS One. 2020;15(10):e0240794. doi:10.1371/journal.pone.024079433079961
   PubMed Web of Science ®Google Scholar
• Birkeland S, Storm H, Lamm L, et al. Cancer risk after renal transplantation in the Nordic countries, 1964–1986. Int J Cancer. 1995;60:183–189. doi:10.1002/ijc.29106002097829213
   PubMed Web of Science ®Google Scholar
• Hortlund M, Arroyo Muhr LS, Storm H, Engholm G, Dillner J, Bzhalava D. Cancer risks after solid organ transplantation and after long-term dialysis. Int J Cancer. 2017;140(5):1091–1101. doi:10.1002/ijc.3053127870055
   PubMed Web of Science ®Google Scholar
• Rama I, Grinyo JM. Malignancy after renal transplantation: the role of immunosuppression. Nat Rev Nephrol. 2010;6(9):511–519. doi:10.1038/nrneph.2010.10220736984
   PubMed Web of Science ®Google Scholar
• Pukkala E, Engholm G, Hojsgaard Schmidt LK, et al. Nordic Cancer Registries - an overview of their procedures and data comparability. Acta Oncol. 2018;57:440–455. doi:10.1080/0284186X.2017.140703929226751
   PubMed Web of Science ®Google Scholar
• Bernstein C, Bernstein H. Epigenetic reduction of DNA repair in progression to gastrointestinal cancer. World J Gastrointest Oncol. 2015;7(5):30–46. doi:10.4251/wjgo.v7.i5.3025987950
   PubMed Web of Science ®Google Scholar
• Marongiu F, Laconi E. Cell competition in liver carcinogenesis. World J Hepatol. 2020;12(8):475–484. doi:10.4254/wjh.v12.i8.47532952874
   PubMed Web of Science ®Google Scholar
• van Doeveren T, van de Werken HJG, van Riet J, et al. Synchronous and metachronous urothelial carcinoma of the upper urinary tract and the bladder: are they clonally related? A systematic review. Urol Oncol. 2020;38:590–598. doi:10.1016/j.urolonc.2020.01.00832057596
   PubMed Web of Science ®Google Scholar
• Fridman WH, Zitvogel L, Sautes-Fridman C, Kroemer G. The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol. 2017;14(12):717–734. doi:10.1038/nrclinonc.2017.10128741618
   PubMed Web of Science ®Google Scholar
• Shalapour S, Karin M. Pas de Deux: control of anti-tumor immunity by cancer-associated inflammation. Immunity. 2019;51(1):15–26. doi:10.1016/j.immuni.2019.06.02131315033
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Vitale I, Warren S, et al. Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. J Immunother Cancer. 2020;8(1):e000337. doi:10.1136/jitc-2019-00033732209603
   PubMed Web of Science ®Google Scholar
• Mondino A, Manzo T. To remember or to forget: the role of good and bad memories in adoptive T cell therapy for tumors. Front Immunol. 2020;11:1915. doi:10.3389/fimmu.2020.0191532973794
   PubMed Web of Science ®Google Scholar
• Liu X, Hemminki K, Forsti A, Sundquist K, Sundquist J, Ji J. Cancer risk in patients with type 2 diabetes mellitus and their relatives. Int J Cancer. 2015;137:903–910. doi:10.1002/ijc.2944025604005
   PubMed Web of Science ®Google Scholar
• Thomsen H, Li X, Sundquist K, Sundquist J, Försti A, Hemminki K. Familial risks between Graves disease and Hashimoto thyroiditis and other autoimmune diseases in the population of Sweden. J Transl Autoimmun. 2020;3:100058. doi:10.1016/j.jtauto.2020.10005832743538
   PubMedGoogle Scholar
• Chen YK, Lin CL, Chang YJ, et al. Cancer risk in patients with Graves’ disease: a nationwide cohort study. Thyroid. 2013;23(7):879–884. doi:10.1089/thy.2012.056823421548
   PubMed Web of Science ®Google Scholar
• Dias Lopes NM, Mendonça Lens HH, Armani A, Marinello PC, Cecchini AL. Thyroid cancer and thyroid autoimmune disease: a review of molecular aspects and clinical outcomes. Pathol Res Pract. 2020;216(9):153098. doi:10.1016/j.prp.2020.15309832825964
   PubMed Web of Science ®Google Scholar
• Hińcza K, Kowalik A, Kowalska A. Current knowledge of germline genetic risk factors for the development of non-medullary thyroid cancer. Genes. 2019;10(7):482. doi:10.3390/genes10070482
   Web of Science ®Google Scholar
• Hemminki K, Eng C, Chen B. Familial risks for nonmedullary thyroid cancer. J Clin Endocrinol Metab. 2005;90:5747–5753. doi:10.1210/jc.2005-093516030170
   PubMed Web of Science ®Google Scholar
• Ertel AE, Bentrem D, Abbott DE. Gall bladder cancer. Cancer Treat Res. 2016;168:101–120.29206367
   PubMedGoogle Scholar
• Mellemkjaer L, Friis S, Olsen JH, et al. Risk of second cancer among women with breast cancer. Int J Cancer. 2006;118:2285–2292. doi:10.1002/ijc.2165116342146
   PubMed Web of Science ®Google Scholar